Start-Up Spotlight: Fractyl Attacks Insulin Resistance At Its Roots
The company is developing a novel duodenal mucosal resurfacing technology designed to reverse the metabolic process that causes insulin resistance in people with type 2 diabetes.
You may also be interested in...
The series F financing will allow the company to expand clinical research supporting its unique duodenal mucosal resurfacing approach to treating metabolic disease at its source.
The US FDA approved Abbott’s new Epic Plus stented tissue mitral valve and Epic Plus Supra stented tissue aortic valve.
BK Medical’s intraoperative imaging and surgical navigation technologies will help GE Healthcare’s ultrasound business expand outside diagnostic imaging into surgical and therapeutic interventions.